Future Directions of Canakinumab and Unmet Needs in NSCLC
Edward B. Garon, MD, MS, discusses data from the phase 3 CANOPY-A study and what they mean for the future of canakinumab for patients with non–small cell lung cancer.
Discussing the Option of Canakinumab in NSCLC
Edward B. Garon, MD, MS, discusses the mechanism of action of canakinumab.
Canakinumab Fails to Improve DFS in Resected NSCLC
Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.
Dr. Edward Garon on the Future of Combination Treatments in Lung Cancer
Garon says the likely place to start when looking into combination therapies are cytotoxic chemotherapy and tyrosine kinase inhibitors, given these treatments are currently approved in lung cancer.
2 Clarke Drive Cranbury, NJ 08512